Closed Clinical Trials
The table below contains a list of all ECOG-ACRIN clinical trials that have closed to enrollment since January 1, 2021. Hover over any of the column headings and click the up/down arrows to sort. You can also search by keyword. To access more information about a particular trial, click on the trial ID, which will link you to more information.
| Cancer Type | Target Patient Population | Trial ID & Link to info | Study Type | ECOG-ACRIN Oversight Committee(s) | Date Closed |
|---|---|---|---|---|---|
| Various | Metastatic (advanced) solid tumors, lymphomas, or myeloma and also rare cancer types with no standard treatment available | EAY131 / NCI-MATCH | Treatment | Developmental Therapeutics | 12/23/22 |
| Various | Metastatic (advanced) solid tumors that are progressing after treatment with taxane chemotherapy | EAY191-E4 / ComboMATCH-E4 | Treatment | Developmental Therapeutics | 11/20/24 |
| Any | Women with a recent cancer diagnosis | E1Q11 / EROS | Reproductive Health Planning | Cancer Control and Survivorship | 03/10/21 |
| Any | Current smokers wanting to stop | EAQ171CD | Observation (Counseling) | Cancer Care Delivery Research | 12/23/22 |
| Any | Cancer patients with pneumonitis (lung inflammation) | EAQ172 | Treatment | Cancer Control and Survivorship | 12/14/23 |
| Anus | Metastatic (advanced) | EA2165 | Treatment | Gastrointestinal | 08/31/21 |
| Anus | Metastatic (advanced), not able to be removed by surgery (inoperable) | EA2176 | Treatment | Gastrointestinal | 09/23/24 |
| Anus | Squamous cell type, no prior treatment | EA2182 / DECREASE | Treatment | Gastrointestinal | 10/30/24 |
| Bile Duct | Metastatic (advanced) cholangiocarcinoma | EA2187 | Treatment | Gastrointestinal | 03/22/23 |
| Bladder | Has spread to the lymph nodes | EA8185 / INSPIRE | Treatment | Genitourinary | 10/02/23 |
| Blood | Hodgkin lymphoma | E4412 | Treatment | Lymphoma | 09/04/24 |
| Blood | Mantle cell lymphoma | EA4151 | Treatment | Lymphoma | 10/03/24 |
| Blood | Mantle cell lymphoma | EA4181 | Treatment | Lymphoma | 03/31/23 |
| Blood | Acute promyelocytic leukemia (AML) | EA9131 | Treatment | Leukemia; Cancer Control and Survivorship | 06/25/21 |
| Blood | Acute lymphoblastic leukemia (ALL) | EA9152 | Treatment | Leukemia | 10/15/24 |
| Blood | Chronic lymphocytic leukemia (CLL) | EA9161 | Treatment | Leukemia | 04/23/21 |
| Blood | Chronic myelogenous leukemia (CML) | EA9171 / BLAST MRD CML 1 | Treatment | Leukemia | 12/17/24 |
| Blood | Previously diagnosed with multiple myeloma and on lenalidomide | EAA171 / OPTIMUM | Treatment | Myeloma | 03/03/23 |
| Blood | Suspected myelodysplastic syndrome | NHLBI-MDS / The National MDS Study | Screening/Early Detection | Leukemia | 06/24/24 |
| Blood | Acute myeloid leukemia with FLT3 mutation | PrE0905 | Treatment | N/A (PrECOG) | 11/17/22 |
| Brain | Recurrent glioblastoma | EAF151 | Imaging | Brain Cancer Working Group | 08/24/23 |
| Breast | Newly diagnosed, metastatic (advanced) | EAI142 | Imaging | Breast | 07/06/22 |
| Breast | Women who decline the TMIST breast cancer screening trial | EAQ201 | Observation (Patient Reporting)) | Cancer Control and Survivorship | 02/02/23 |
| Breast | Black women with breast cancer | EAZ171 | Treatment | Breast; Prevention | 03/31/22 |
| Breast | Women planning for regular mammograms | EA1151 / TMIST | Screening/Early Detection | Imaging; Prevention; Breast | 12/20/24 |
| Breast | Metastatic (advanced) with bone or mostly bone disease | EA1183 / FEATURE | Imaging | Breast | 11/29/23 |
| Breast | Triple negative and basal subtype, including both women and men | EA1131 | Treatment | Breast | 03/30/21 |
| Breast | HER2 positive type | EA1181 / CompassHER2 pCR | Treatment | Breast | 10/12/23 |
| Esophagus and Stomach | Metastatic (advanced), HER2 negative type | EA2183 | Treatment | Gastrointestinal | 05/23/25 |
| Gallbladder | Discovered at time of surgery to remove the gallbladder | EA2197 / OPT-IN | Treatment | Gastrointestinal | 04/18/25 |
| Head and Neck | Metastatic (advanced) squamous cell type that has returned after treatment with immune checkpoint inhibitors | EA3202 | Treatment | Head and Neck | 05/1/25 |
| Kidney | Localized (no spread) or limited spread | EA8143 / PROSPER RCC | Treatment | Genitourinary | 06/02/21 |
| Kidney | Metastatic (advanced) renal cell carcinoma | EA8211 / SOAR | Treatment | Genitourinary | 05/29/25 |
| Kidney or Thyroid | Blood pressure management | EAQ191 / CARISMA | Treatment | Cancer Control and Survivorship | 12/27/23 |
| Liver | Metastatic (advanced) or not able to be removed by surgery (inoperable) | EA2205 | Treatment | Gastrointestinal | 05/07/24 |
| Lung | Non-small cell type, metastatic (advanced) | EA5163 / S1709 / INSIGNA | Treatment | Thoracic | 03/01/24 |
| Lung | Non-small cell type, not able to be removed by surgery (inoperable) | EA5181 | Treatment | Thoracic | 11/20/23 |
| Lung | Non-small cell, non-squamous type | EA5191 | Treatment | Thoracic | 10/13/23 |
| Lung | Non-small cell type, able to be removed by surgery (operable) | E4512, an ALCHEMIST Trial | Treatment | Thoracic | 05/10/24 |
| Lung | Pleural mesothelioma | PrE0506 / DREAM3R | Treatment | N/A (PrECOG) | 09/22/23 |
| Melanoma (Skin) | Melanoma, metastatic (advanced), and BRAF V600 type | EA6134 / DREAMseq | Treatment | Melanoma | 09/30/21 |
| Melanoma (Skin) | Cutaneous or unknown primary type | EA6183 | Treatment | Melanoma | 09/23/22 |
| Melanoma (Skin) | Advanced, BRAF V600E or BRAF V600K type, and elevated LDH | EA6191 / BAMM2 | Treatment | Melanoma | 03/01/23 |
| Melanoma (Skin) | Able to be removed by surgery (operable) | EA6194 | Treatment | Melanoma | 01/28/25 |
| Merkel Cell (Skin) | Able to be removed by surgery (operable) | EA6174 / STAMP | Treatment | Melanoma | 07/01/24 |
| Nose and Sinus | Squamous cell type, able to be removed by surgery (operable) | EA3163 | Treatment | Head and Neck | 11/07/23 |
| Pancreas or Gastrointestinal Tract | Locally advanced or metastatic, inoperable | EA2142 | Treatment | Gastrointestinal | 04/01/21 |
| Pancreas | Metastatic (advanced), older (aged 70+) | EA2186 / GIANT | Treatment | Gastrointestinal; Geriatric Oncology Working Group | 10/17/23 |
| Prostate | Metastatic (advanced), hormone sensitive type | EA8153 / CHAARTED2 | Treatment | Genitourinary | 03/26/21 |
| Prostate | Newly diagnosed, before surgery | EA8171 | Imaging/Treatment Planning | Genitourinary | 01/28/25 |
| Prostate | Within 6 weeks of surgery (radical prostatectomy) and at highest risk of progression to metastatic (advanced) stage | EA8183 / ERADICATE | Treatment | Genitourinary | 02/09/23 |
| Rectum | Locally advanced, MSI-H or dMMR type | EA2201 | Treatment | Gastrointestinal | 01/14/25 |
| Stomach | Gastric (stomach) and/or gastroesophageal junction cancer, able to be removed by surgery (operable) | EA2212 | Treatment | Gastrointestinal | 12/04/24 |